Vaccines to treat cancer-an old approach whose time has arrived

Journal of Cellular Biochemistry

Volumn 102, Issue 2, 2007, Pages 291-300

  Hellstrom, Karl Erik ^a,b   Hellstrom, Ingegerd ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Harborview R and T UW Department of Neurosurgery   (United States)

Author keywords

Cancer vaccines; Immunotherapy; Targeting

Indexed keywords

ANTIBODY; CANCER VACCINE; CD137 ANTIGEN; DNA; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LYMPHOKINE;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; BYSTANDER EFFECT; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURGERY; GENE MUTATION; HUMAN; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; EPITOPES; HUMANS; IMMUNITY, ACTIVE; IMMUNITY, NATURAL; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS;

EID: 34948815059     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21468     Document Type: Review

References (53)

1. Adamina M, Daetwiler S, Rosenthal R, Zajac P. 2005. Clinical applications of recombinant virus-based cancer immunotherapy. Expert Opin Biol Ther 5:1211-1224.
2. Aklilu M, Stadler WM, Markiewicz M, Vogelzang NJ, Mahowald M, Johnson M, Gajewski TF. 2004. Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma. Ann Oncol 15:1109-1114.
3. Bielas JH, Loeb KR, Rubin BP, True LD, Loeb LA. 2006. Human cancers express a mutator phenotype. Proc Natl Acad Sci USA 103:18238-18242.
4. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. 1994. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12:337-365.
5. Boon T, Coulie PG, Van den Eynde B. 1997. Tumor antigens recognized by T cells. Immunol Today 18:267-268.
6. Chen L, Ashe S, Brady WA, Hellström I, Hellström KE, Ledbetter JA, McGowan P, Linsley PS. 1992. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093-1102.
7. Dhodapkar MV, Steinman RM. 2002. Antigen-bearing immature dendritic cells induce peptide-specific CD8+ regulatory T cells in vivo in humans. Blood 100:174-177.
8. Disis ML, Gooley TA, Rinn K, et al. 2002. Generation of T-cell immunity to the her-2/neu protein after active immunization with her-2/neu peptide-based vaccines. J Clin Oncol 20:2624-2632.
9. Disis M-L, Scholler N, Dahlin A, Pullman J, Hellstrom KE, Hellstrom I. 2003. Plasmid-based vaccines encoding rat neu and immune stimulatory molecules elicit rat neu specific immunity. Mol Cancer Ther 2:1-8.
10. Dong H, Strome SE, Salomao D, Tamura H, Hirano F, Fllies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L. 2002. Tumor-associated B7-H1 promotes T-cell apoptosis. A potential mechanism of immune-evasion. Nat Med 8:793-800.
11. Eager R, Nemunaitis J. 2005. GM-CSF gene-transduced tumor vaccines. Mol Ther 12:18-27.
12. Egen JG, Kuhns MS, Allison JP. 2002. CTLA-4: New insights into its biological function and use in tumor immunotherapy. Nat Immunol 3:611-618.
13. Emens LA. 2006. Roadmap to a better therapeutic tumor vaccine. Int Rev Immunol 25:415-443.
14. Facciponte JG, Wang XY, MacDonald IJ, Park JH, Arnouk H, Grimm MJ, Li Y, Kim HK, Manjili MH, Easton DP, Subjeck JR. 2006. Heat shock proteins HSP70 and G P96: Structural insights. Cancer Immunol Immunother 55: 339-346.
15. Gabrilovich DI, Ciernik IF, Carbone DP. 1996. Dendritic cells in antitumor immune responses. I. defective antigen presentation in tumor-bearing hosts. Cellular Immunol 170:101-110.
16. Gaggar A, Shayakhmetov DM, Lieber A. 2003. CD46 is a cellular receptor for group B adenoviruses. Nat Med 9:1408-1412.
17. Gershon RK, Mokyr MB, Mitchell MS. 1974. Activation of suppressor T cells by tumour cells and specific antibody. Nature 250:594-596.
18. Hellstrom KE, Hellstrom I. 1969. Cellular immunity against tumor specific antigens. Adv Cancer Res 12: 167-223.
19. Hellstrom KE, Hellstrom I. 2003. Novel approaches to therapeutic cancer vaccines. Expert Rev Vaccines 2:517-532.
20. Kiessling R, Wasserman K, Horiguchi S, Kono K, Sjoberg J, Pisa P, Petersson M. 1999. Tumor-induced immune dysfunction. Cancer Immunol Immunother 48:353-362.
21. Kim J, Rasmussen J, Rudensky A. 2007. Regulatory T cells prevent catastrophic autoimmunity throughout the life-span of mice. Nat Immunol 8:1-7.
22. Klein E, Rosner D, Holterman OA, Stoll HL. 1976. Non-specific antigen reactions. In: Lewison EF, editor. Conference on spontaneous regression of cancer. Bethesda, MD: NIH. pp 87-97.
23. Kudo-Saito C, Wansley EK, Gruys ME, Wiltrout R, Schlom J, Hodge JW. 2007. Combination therapy of an orthotopic renal cell carcinoma model using intratumoral vector-mediatedd costimulation and systemic interleukin-2. Clin Cancer Res 13:1936-1946.
24. Larmonier N, et al. 2007. Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. Cancer Immunol Immunother 56:48-59.
25. Li Y, Hellström KE, Ashe Newby S, Chen L. 1996. Costimulation by CD48 and B 7-1induces immunity against poorly immunogenic tumors. J Exp Med 183: 639-644.
26. McSweeney PA, et al. 2001. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97:3390-3400.
27. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE, Mittler RS, Chen L. 1997. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 3:682-685.
28. Melero I, Bach N, Hellstrom KE, Aruffo A, Mittler RS, Chen L. 1998. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: Synergy with the CD28 co-stimulatory pathway. Eur J Immunol 28:1116-1121.
29. Mittler RS, Bailey TS, Klussman K, Trailsmith MD, Hoffmann MK. 1999. Anti-4-1BB monoclonal antibodies
30. abrogate T cell-dependent humoral immune responses in vivo through the induction of helper T cell anergy. J Exp Med 190:1535-1540.
31. Morton DL, Barth A. 1996. Vaccine therapy for malignant melanoma. CA Cancer J Clin 46:225-244.
32. Nava-Parada P, Forni G, Knutson KL, peasse LR, Celis E. 2007. Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. Cancer Res 67:1326-1334.
33. Obeid M, Tesniere A, Ghiringhelli F, et al. 2007. Calreticulin exposure dictatese the immunogenicity of cancer cell ceath. Nature Med 13:54-61.
34. Palena C, Abrams SI, Schlom J, Hodge JW. 2006. Cancer vaccines: Preclinical studies and novel strategies. Adv Cancer Res 95:115-145.
35. Pardoll DM. 1998. Cancer vaccines. Nature Med 4:525-531.
36. Petrulio CA, Kaufman HL. 2006. Development of the PANVAC (TM)-VF vaccine for pancreatic cancer. Expert Rev Vaccines 5:9-19.
37. Prendergast GC, Jaffee EM. 2007. Cancer immunologists and cancer biologists: Why we didn't talk then but need to now. Cancer Res 67:3500-3504.
38. Qin Y, Cheung YK, Cheng C, Wang XH, Meng S, Hu MH, Xie Y. 2007. A DNA vaccine constructed with human papillomavirus type 16 (HPV16) E7 and E6 genes induced specific immune responses. Gynecol Oncol 104: 199-206.
39. Rosenberg SA, Yang JC, Restifo NP. 2004. Cancer immunotherapy: Moving beyond current vaccines. Nat Med 10: 909-915.
40. Schevach EM. 2004. Fatal attraction: Tumors becon regulatory T cells. Nat Med 10:900-901.
41. Sewell DA, Shahabi V, Gunn GR, Pan ZK, Dominiecki ME, Paterson Y. 2004. Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7. Cancer Res 64:8821-8825.
42. Sjogren HO, Hellstrom I, Bansal SC, Hellstrom KE. 1971. Suggestive evidence that the "blocking antibodies" of tumor-bearing individuals may be antigen - antibody complexes. Proc Natl Acad Sci USA 68:1372-1375.
43. Song WR, Levy R. 2005. Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells. Cancer Res 65:5958-5964.
44. Steinman RM, Pope M. 2002. Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 109:1519-1526.
45. Todryk SM, Tutt AL, Green HA, et al. 2001. CD40 ligation for immunotherapy of solid tumors. J Immunol Methods 248:139-147.
46. Vaage J. 1972. Specific desensitization of resistance against a syngeneic methylcholanthrene-induced sarcoma in C3Hf mice. Cancer Res 32 193-199.
47. Vaage J. 1973. Influence of tumor antigen on maintenance versus depression of tumor-specific immunity. Cancer Res 33:493-503.
48. Wei S, Kryczek I, Zou L, Daniel B, Cheng P, Mottram P, Curiel T, Lange A, Zou WP. 2005. Plasmacytoid dendritic cells induce CD8(+) regulatory T cells in human ovarian carcinoma. Cancer Res 65:5020-5026.
49. Wolf DA, et al. 2005. The expression of the regulatory t cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Cancer Res 11:8326-8333.
50. Yang SC, Yang Y, Raycraft J, Zhang H, Kanan S, Guo Y, Hellstrom I, Hellstrom KE. 2004. Tumor cells transfected to express CD83 induce anti-tumor immunity which can be increased by also engaging CD137. Proc Natl Acad Sci USA 101:4990-4995.
51. Yang Y, Yang S, Ye Z, Jaffar J, Zhou Y, Cutter E, Lieber A, Hellstrom I, Hellstrom KE. 2007. Tumor cells expressing anti-CD137 scFv induce a tumor-destructive environment. Cancer Res 67:2339-2344.
52. Ye Z, Hellstrom I, Hayden-Ledbetter M, Dahlin A, Ledbetter JA, Hellstrom KE. 2002. Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB. Nat Med 8:343-348.
53. Zhang H, Knutson L, Hellstrom KE, Disis ML, Hellstrom I. 2006. Antitumor efficacy of CD137 ligation is maximized by the use of a CD137 single-chain Fv-expressing whole-cell tumor vaccine compared with CD137-specific monoclonal antibody infusion. Mol Cancer Ther 5:149-155.